MetaCap

IGC Pharma (IGC) vs Pasithea Therapeutics (KTTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed IGC Pharma (IGC) over the past year, gaining 63.9% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -99.4% for KTTA. IGC Pharma is the larger company by market cap ($19.6 million vs $17.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IGC-47.50%KTTA+63.94%
+426%+178%-70%
Nov 21, 20251 yearNov 20, 2026
IGC-88.25%KTTA-98.99%
+78%-15%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IGC versus KTTA key metrics
MetricIGCKTTA
Share price$0.168$0.4787
Market cap$19.60M$17.59M
1-day change-8.70%-0.48%
YTD return-40.00%-62.89%
1-year return-47.50%+63.94%
5-year return-87.65%-99.40%
EPS (TTM)$-0.07$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.27M—
Revenue growth (YoY)-5.50%—
Net income (latest FY)$-7.12M$-20.43M
Gross margin48.70%—
Operating margin-585.84%—
Net margin-560.35%—
52-week high$0.36$2.06
52-week low$0.08$0.32
Distance from 52-week high-53.33%-76.76%
Analyst consensusnonenone
Avg. price target upside+3471.43%+526.70%
Average volume615.25K705.64K
Shares outstanding116.69M36.75M
Employees705
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed IGC by 111.4 percentage points over the past year.

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

IGC vs KTTA FAQ

Which is bigger, IGC Pharma or Pasithea Therapeutics?

IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $17.59M for Pasithea Therapeutics (KTTA).

Which stock has performed better over the past year, IGC or KTTA?

KTTA returned +63.94% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.

Are IGC Pharma and Pasithea Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons